D'Andrea Named President, Chief Scientific Officer at ImmuneID
5 April 2021 - - US-based precision immunology company ImmuneID, Inc has appointed Annalisa D'Andrea, Ph.D. as president and chief scientific officer, the company said.

Dr. D'Andrea brings more than 25 years of experience in translational research in immunology to ImmuneID.

The announcement of Dr. D'Andrea as president and CSO follows the launch of the company last year with a USD 22m seed financing led by founding investor Longwood Fund. Participants in the financing included Arch Venture Partners, Pitango HealthTech, Alta Partners, In-Q-Tel, Xfund, and others.

ImmuneID plans to use this funding to develop therapeutic programs in areas including severe allergy, autoimmunity, oncology, and infectious disease.

In addition to her appointment at ImmuneID, Dr. D'Andrea joins the Longwood Fund as a Venture Partner.

Previously, Dr. D'Andrea was chief scientific officer of Kiniksa Pharmaceuticals. Before joining Kiniksa, D'Andrea was vice president and Global Head of Discovery for Immunology and Inflammation at Roche, where she was responsible for discovering and advancing multiple drug candidates to the clinic.

Prior to Roche, she was executive director and Section Head of Discovery Biology at SRI International, where she was responsible for developing strategies to advance drugs through discovery and into development.

Dr. D'Andrea received a Bachelor of Sciences, summa cum laude, from the University of Siena in Italy and a doctoral degree from the University of Florence while training at the Wistar Institute at the University of Pennsylvania.

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), we are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.

ImmuneID was founded in 2020 by Longwood Fund and is headquartered in Cambridge, MA.